Aktuellt
SENASTE
Redeye provides an additional comment on the news that Egetis Therapeutics has secured in total SEK462m in funding, including SEK172m from a directed issue/private placement. We see this as a significant de-risk and argue that the positive reaction in the share price is warranted given the low expectations baked into today’s valuation.
LÄS MER
